AGC Biologics, a pharma contract development and manufacturing organisation (CDMO) based in the US, expanded its production capacity by opening a new manufacturing building at its Copenhagen campus in Denmark. The new facility features a flexible and efficient setup for manufacturing biologic drug substances. It enhanced the company’s capacity in Europe by effectively doubling its mammalian-based clinical supply and commercial manufacturing capabilities, thereby addressing the needs of both new and existing clients.
AGC Biologics announced the project in November 2020. The facility was completed in June 2024, with an investment of €200m ($239m). However, the facility began operations earlier with a Phase II/III clinical product for a customer.
The project created an estimated 250 to 300 new job opportunities in Denmark. AGC Biologics Copenhagen facility expansion details The new state-of-the-art mammalian multipurpose building spans a total area of 19,000m2. Distributed across four levels, it houses manufacturing facilities, quality control laboratories, technical areas, and warehouse space.
The production focuses on genetically modified organisms at biosafety level 1, utilising single-use technology in dedicated . The site’s multiple single-use suites facilitate technical transfers and process operations for incoming products, minimising delays and ensuring efficient integration of new CDMOs. The 3,300m2 good manufacturing practice (cGMP) manufacturing area features ei.
